Attached files
| file | filename |
|---|---|
| EX-3.1 - ENDONOVO THERAPEUTICS, INC. | ex3-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 17, 2017
ENDONOVO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 333-176954 | 45-2552528 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367
(Address of principal executive office)(Zip Code)
Registrant’s telephone number, including area code: (800) 489-4774
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 3.03 Material Modification to Rights of Security Holders.
On January 17, 2017, we filed a certificate of amendment to our certificate of incorporation which increased the number of shares of shares of common stock that we are authorized to issue from 250,000,000 shares to 500,000,000 shares (the “Amendment”). The Amendment was approved by our board of directors and by the majority in voting interest of our shareholders. We advised our shareholders through an Information Statement under regulation 14C under the Securities and Exchange Act of 1934, as amended, that we intended to file the Amendment.
Item 9.01 Financial Statements and Exhibits.
| (a) | Financial Statements -None | |
| (b) | Exhibits | |
3.1 Certificate of Amendment filed January 17, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 18, 2017
| ENDONOVO THERAPEUTICS, INC. | ||
| By: | /s/ Alan Collier | |
Alan Collier | ||
| Chief Executive Officer | ||